Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Placebo-Controlled, Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, (MMRIIÒ) and Varicella (VARIVAXÒ) Vaccines Administered Concurrently to Healthy Children (AV018)
Brief Summary: * To compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children who receive an intranasal placebo mist concurrently with MMRIIÒ and VARIVAXÒ (Group 2 vs. Group 1).
* To compare immune responses to the three strains of influenza (H1N1, H3N2, and B) following a two dose regimen of FluMist in children who receive the initial FluMist dose concurrently with MMRIIÒ and VARIVAXÒ and in children who receive two doses of FluMist alone (Group 2 vs. Group 3).Secondary:
* To assess the safety and tolerability of concurrent administration of FluMist with MMRIIÒ and VARIVAXÒ.


Options:
A: Anti-Polyribosyl Ribitol Phosphate (PRP) Antibody Concentrations (One month after primary vaccination); Neisseria Meningitidis Serogroup C (MenC) Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers (One month after primary vaccination); Neisseria Meningitidis Serogroup Y (MenY) Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers (One month after primary vaccination); hSBA-MenC Antibody Titers (Prior to the fourth dose vaccination and 42 days after the fourth dose); hSBA-MenY Antibody Titers (Prior to the fourth dose vaccination and 42 days after the fourth dose); Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter (µg/mL) (One month after primary vaccination); Number of Subjects With hSBA-MenC Titer Equal to or Above 1:8 (42 days after the fourth dose); Number of Subjects With hSBA-MenY Titer Equal to or Above 1:8 (42 days after the fourth dose); Number of Subjects With Anti-measles Antibody Concentrations Equal to or Above 150 Milli-international Units Per Milli-liter (mIU/ML) (42 days after the fourth dose); Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter (42 days after the fourth dose); Number of Subjects With Anti-mumps Titer Equal to or Above 28 Estimated Dose 50 (ED50) (42 days after the fourth dose); Number of Subjects With Anti-rubella Antibody Concentrations Equal to or Above 10 International Units Per Milli-litre (IU/mL) (42 days after the fourth dose); Number of Subjects With Anti-varicella Titer Equal to or Above 1:5 (42 days after the fourth dose)
B: Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers (One month after the second vaccination (Month 3)); Frequency Odds Ratio of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers (One month after the second vaccination (Month 3)); Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers (One month after the second vaccination (Month 3))
C: Antibody levels after vaccination.
D: compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children (Day 42)

Answer: D